LUNGevity Launches New Gateway for Small Cell Lung Cancer Patients

Specialized resource offers small cell lung cancer (SCLC) patients and their caregivers access to treatment information, informative webinars, the latest scientific news and a supportive community

WASHINGTON, August 16, 2022 /PRNewswire/ — LUNGevity Foundation, the nation’s leading nonprofit focused on lung cancer, has launched the Gateway for patients with small cell lung cancer. This new resource completes the suite of six Patient Gateways, where lung cancer survivors can access relevant information tailored to their specific subtype. Small cell lung cancer accounts for 15% of all lung cancers and is often diagnosed in people with a history of smoking. The gateway makes it easier for survivors to locate specialists and resources. The Patient Gateway also offers information about treatment options and the ability to connect with a community of other survivors and their caregivers.

“Due to the aggressive nature of small cell lung cancer, it is especially important that survivors have access to accurate information and the latest news about treatment options and new clinical trials,” said Andrea Ferris, President and CEO of the LUNGevity Foundation. “We hope that patients and their caregivers will be empowered by the information they find on the Patient Gateway and can use what they learn to be active decision makers in their treatment.”

The Small Cell Lung Cancer Patient Gateway is a user-friendly, easily accessible information portal that offers the latest medical updates and practical resources for patients and their caregivers. The gateway, available at sclc.lungevity.org, provides visitors with information about the disease and how it is treated. Visitors can also find a specialist, join a variety of patient and caregiver communities, explore clinical trial options, and read up-to-the-minute news and trends. Each individual gateway features expert webinars and blogs, patient and caregiver stories, and quarterly newsletters.

The Small Cell Lung Cancer Patient Gateway joins the EGFR, KRAS, ALK, Rare Mutations and Fusions and Non-Small Cell Lung Cancer (NSCLC) platforms at gateway.lungevity.org.

The Small Cell Lung Cancer Patient Gateway is supported by generous sponsorships from AstraZeneca, EMD Serono, Genentech and Jazz Pharmaceuticals.

About the LUNGevity Foundation

LUNGevity Foundation is the leading national lung cancer organization focused on improving outcomes for people with lung cancer. The foundation works tirelessly to advance research into early detection and more effective treatments, and to ensure that patients have access to these advances. LUNGevity seeks to have an immediate impact on the quality of life and survival of all people affected by the disease, while promoting health equity by addressing disparities along the continuum of care. LUNGevity provides information and educational tools to empower patients and their caregivers, promote impactful public policy initiatives, and amplify patient voices through research and engagement. The organization provides an active community for patients and survivors – and those who help them live better, longer lives.

Comprehensive resources include a medically vetted and patient-centered website, a toll-free helpline, the International Lung Cancer Survivorship Conference, and an easy-to-use clinical trial search tool, among other tools. All of these programs aim to achieve our vision: a world where no one dies from lung cancer. The LUNGevity Foundation is proud to be a four-star Charity Navigator organization.

About Lung Cancer in the United States

  • About 1 in 17 Americans will be diagnosed with lung cancer in their lifetime.
  • More than 236,000 people in the United States will be diagnosed with lung cancer this year.
  • About 60-65% of all new lung cancer diagnoses are in people who have never smoked or are former smokers.
  • Lung cancer takes more lives United States than the two deadliest cancers (colorectal and pancreatic) combined.
  • Only about 23% of all people diagnosed with lung cancer in United States will survive 5 years or more, BUT if caught before it spreads, the chances of survival at 5 years improve dramatically.

Please visit lungevity.org to learn more.

SOURCE LUNGevity Foundation

About Wanda Reilly

Check Also

Japan’s $2 billion initiative to prepare pandemic vaccines in 100 days

A new Japanese research effort will work on vaccines against infectious diseases, including coronaviruses, monkeypox …